Chapter from the book *Soybean - Biochemistry, Chemistry and Physiology*
Downloaded from: http://www.intechopen.com/books/soybean-biochemistry-chemistry-and-physiology

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
10

Protease Inhibitors, Lectins, Antifungal Protein and Saponins in Soybean

NgTB1, Cheung Randy CF1, Ye X J1, Wong Jack H1 and Ye X Y2
1School of Biomedical Sciences, Faculty of Medicine. The Chinese University of Hong Kong, Shatin, New Territories Hong Kong
2College of Biological Science and Technology, FuZhou University, FuZhou. 350002 China

1. Introduction

Many investigations have been conducted on soybean during the past decade since it is a unique dietary source of isoflavones which display a diversity of biological activities and reduce the risk of some chronic diseases. Soybean is distinctive in that it has a high content of isoflavones which allegedly diminish the risk of cancer, cardiovascular disease, and osteoporosis, and also alleviate menopausal symptoms. Isoflavones are weakly estrogenic. The isoflavone genistein also affects signal transduction. Soyfoods and isoflavones have arrested the attention of many researchers on account of their potential role in preventing and treating cancer and osteoporosis. The low breast cancer mortality rates in Asia and the putative antiestrogenic infer that soyfood intake reduces breast cancer risk. Soy or isoflavones may decrease the risk of prostate cancer. The low estrogenic activity of soybean isoflavones and their structural resemblance to the synthetic isoflavone ipriflavone, which elevates bone mineral density in postmenopausal women, suggest that soy or isoflavones may decrease the risk of osteoporosis.

Besides isoflavones, soybean also produces protease inhibitors, lectins, and antifungal proteins, which have important biological activities. This review encompasses a discussion of isoflavones, protease inhibitors, lectins and antifungal proteins.

2. Protease inhibitors

Protease inhibitors in soybeans can reduce protein digestion, and induce pancreatomegaly and enhance chemically induced pancreatic tumors in some animals (Grant, 1989). The quantity of protease inhibitors ingested would not have any adverse consequences in humans (Liener, 1994). The trypsin / chymotrypsin inhibitor (Bowman-Birk inhibitor) found in soybeans has been studied as an anticancer agent (Kennedy, 1995).

A large number of protease inhibitors belonging to various types have been purified from different kinds of legumes. In the study of Fang et al. (2010b), by using liquid chromatography techniques, a Kunitz type trypsin inhibitor (KBTI) was isolated from Korean large black soybeans. It exhibited a molecular mass of 20107.645 Da and inhibited the proteases trypsin and alpha-chymotrypsin with an activity of 8520 BAEE units/mg and
24 BTEE units/mg, respectively. Its trypsin inhibitory activity demonstrated pronounced thermal stability (0-100 °C) and stability over a wide range of pH values (pH 3-11). KBTI reduced the activity of HIV-1 reverse transcriptase activity with an IC₅₀ value of 0.71 μM. It evoked the release of pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-2 and interferon-gamma at the mRNA level. KBTI exerted low antiproliferative activity toward CNE-2 and HNE-2 nasopharyngeal cancer cells, MCF-7 breast cancer cells, and Hep G2 hepatoma cells. It was devoid of mitogenic, ribonuclease and antifungal activities. A 19-kDa trypsin inhibitor with an N-terminal amino acid sequence highly homologous to Kunitz-type trypsin inhibitors was purified from seeds of Chinese black soybean Glycine max cv. "Small Glossy Black" using a procedure that involved anion exchange chromatography on Q-Sepharose, cation exchange chromatography on SP-Sepharose and anion exchanger chromatography on DEAE-cellulose. It was bound on all three ion exchangers. It inhibited trypsin with an IC₅₀ of 19 μM and chymotrypsin with an IC₅₀ of 14.3 μM. Its trypsin inhibitory activity was relatively pH stable and thermostable. It was preserved in the pH range pH 3-pH 13 and in the temperature range 0 °C-60 °C. The trypsin inhibitory activity was reduced in the presence of dithiothreitol (from 5 to 25 mM) in a dose-dependent manner indicating the paramount importance of disulphide bonds to the activity. It inhibited HIV-1 reverse transcriptase with an IC₅₀ of 0.16 μM, and exerted antiproliferative activity toward MCF-7 breast cancer cells with an IC₅₀ of 4.3 μM and HepG2 hepatoma cells with an IC₅₀ higher than 25 μM. The trypsin inhibitor was devoid of antifungal activity and mitogenic activity towards mouse splenocytes (Ye and Ng, 2009a). A trypsin inhibitor from the seeds of Hokkaido large black soybeans possessed an N-terminal amino acid sequence that closely resembled those of 8-kDa Bowman-Birk trypsin inhibitors. The trypsin inhibitor was unbound on SP-Sepharose but bound on the anion exchangers DEAE-cellulose and Mono Q. It exerted antiproliferative activity toward breast cancer (MCF-7) cells and hepatoma (HepG2) cells with an IC₅₀ of 35 and 140 μM, respectively. The trypsin inhibitory activity of the inhibitor was retained following thermal treatment up to 100 °C for 30 min and after exposure to the pH range 2-13 for the same duration. The trypsin inhibitor inhibited HIV-1 reverse transcriptase with an IC₅₀ of 38 μM. Moreover, there was no antifungal activity toward Fusarium oxysporum and Mycosphaerella arachidicola (Ho and Ng, 2008). Chinese ‘Large Black Soybeans’ produce a 60-kDa lectin and a 20 kDa trypsin inhibitor. Both proteins were absorbed on Q-Sepharose, but could be separated from one another on Mono Q. Further purification was achieved by gel filtration on Superdex 75. Both trypsin inhibitor and lectin were stable from pH 3 to 13 and from 0 °C to 65 °C. The trypsin inhibitor was stable at pH as low as 2, and it inhibited trypsin and chymotrypsin with an IC₅₀ of 5.7 μM and 5 μM, respectively. Its trypsin inhibitory activity was reduced in the presence of dithiothreitol indicating the importance of the disulphide bond to the activity. Both trypsin inhibitor and lectin inhibited HIV-1 reverse transcriptase (IC₅₀ = 44 and 26 μM) and proliferation of HepG2 hepatoma cells (IC₅₀ = 9 μM and 17 μM) and MCF7 breast cancer cells (IC₅₀ = 42 and 13.5 μM) (Ye and Ng, 2009b). Studies utilizing different types of protease inhibitors as anticarcinogenic agents in vivo and in vitro systems have recently been reviewed. These studies suggest that the protease inhibitors which prevent carcinogenesis affect processes in the early stages of carcinogenesis, although they can be effective at long time periods after carcinogen exposure in both in vitro and in vivo systems. While there is strong evidence that these protease inhibitors can affect both the initiation and promotion stages of carcinogenesis, they have no
effect on already transformed cells. The results have suggested that the first event in carcinogenesis is a high frequency epigenetic event and that a later event, presumably genetic, leads to the malignant state. Protease inhibitors appear capable of reversing the initiating event, presumably by stopping an ongoing cellular process begun by carcinogen exposure. The major lines of investigation on the mechanism of the protease inhibitor suppression of carcinogenesis relate to the ability of anticarcinogenic protease inhibitors to affect the expression of certain oncogenes, and the levels of certain types of proteolytic activities. The anticarcinogenic protease inhibitors have no observable effects on normal cells, but can reverse carcinogen-induced cellular changes for several different end-points studied. The most direct method of determining the mechanism of action of the anticarcinogenic protease inhibitors is to identify and characterize the proteases with which they interact. In the cells of the in vivo and in vitro systems in which protease inhibitors can prevent carcinogenesis, only a few proteases have been observed to interact with the anticarcinogenic protease inhibitors. Proteases have been identified by both substrate hydrolysis and affinity chromatography (Kennedy, 1995).

3. Lectins

Lectins, a class of proteins that reversibly and non-enzymatically bind specific sugars, have been purified from different kinds of legumes. In the study of Fang et al. (2010a), a lectin (KBL) with a molecular mass of 48 kDa was isolated from Korean large black soybeans. The specific hemagglutinating activity of the lectin was 4096 titer/mg. The metal chelator EDTA brought about a decline of hemagglutinating activity. The activity could be reinstated by addition of Fe$^{3+}$ ions and divalent cations such as Ca$^{2+}$, Mn$^{2+}$, Fe$^{2+}$, Cu$^{2+}$, Zn$^{2+}$, and Pb$^{2+}$. The lectin was specific to sugars including D-(+)-galactose, D-(+)-raffinose, L-(+)-arabinose, alpha-D-(+)-melibiose, and alpha-lactose, the hemagglutinating activity of the lectin could be inhibited by these sugars. The lectin manifested remarkable thermal stability and stability over a wide range of pH values. The lectin demonstrated HIV-1 reverse transcriptase inhibitory activity with an IC$_{50}$ of 1.38 μM. However, it lacked antifungal, cytokine inducing, mitogenic and ribonuclease activities. In addition, it did not inhibit proliferation of nasopharyngeal cell lines at concentrations up to 20 μM.

A lectin was purified from the seeds of the cultivar of soybean (Glycine max), called the small glossy black soybean. The purification protocol involved anion exchange chromatography on Q Sepharose, cation exchange chromatography on SP Sepharose and fast protein liquid chromatography anion exchange chromatography on Mono Q followed by gel filtration on Superdex 75. The dimeric 50 kDa melibiose-binding lectin with an N-terminal sequence identical to that of soybean lectin was bound on all three ion exchangers. Of all the sugars tested, melibiose most potently inhibited the hemagglutinating activity of the lectin. The lectin was stable between pH 3-12 and 0-70 °C. The lectin elicited maximal mitogenic response from murine splenocytes at about the same molar concentration as Con A. Although the magnitude of the maximal response was smaller, the soybean lectin suppressed the activity of HIV-1 reverse transcriptase and exerted antiproliferative activity toward breast cancer MCF7 cells and hepatoma HepG2 cells with an IC$_{50}$ of 2.82 μM, 2.6 μM and 4.1 μM, respectively. The lectin lacked antifungal activity. Another lectin isolated from a different cultivar of soybean called little black soybean was grossly similar to small glossy black soybean lectin but the former had a larger subunit molecular mass (31 kDa), a more potent mitogenic activity and lower thermostability. The data suggest that different soybean cultivars produce similar but not identical lectins (Lin et al., 2008).
4. Antifungal proteins

A 25 kDa monomeric antifungal protein with an N-terminal amino acid sequence exhibiting homology to a segment of chitin synthase, was purified from the seeds of the black soybean *Glycine soja*. The protein was designated as glysojanin. It potently inhibited mycelial growth of the fungi *Fusarium oxysporum* and *Mycosphaerella arachidicola*. It inhibited HIV-1 reverse transcriptase with an IC$_{50}$ of 47 μM, [methyl-$^{3}$H]thymidine incorporation by mouse splenocytes with an IC$_{50}$ of 175 μM, and $^{3}$H-leucine incorporation into proteins in the cell-free rabbit reticulocyte lysate with an IC$_{50}$ of 20 μM. The isolation protocol involved anion-exchange chromatography on DEAE-cellulose, affinity chromatography on Affi-gel blue gel, cation-exchange chromatography by fast protein liquid chromatography on Mono S, and gel filtration by fast protein liquid chromatography on Superdex 75 (Ngai and Ng, 2008).

5. Saponins

Saponins are glycosides composed of a lipid-soluble aglycone consisting of either a sterol or, more often, a triterpenoid structure linked to water-soluble sugar residues that vary in their type and quantity. Legumes are the major sources of dietary saponins. The same bean can have different types of saponins. Saponins are very poorly absorbed. Most saponins form insoluble complexes with 3-β-hydroxysteroids and interact with and form large, mixed micelles with bile acids and cholesterol. Although saponins were shown to lower cholesterol in some animal species, the hypocholesterolemic effects of saponins in humans are more speculative (Milgate and Roberts, 1995). Saponins may have anticancer properties, as suggested by a recent rodent study that found that a saponin-containing diet (3% by wt) inhibited by about two-thirds the development of azoxymethane-induced preneoplastic lesions in the colon (Koratkar and Rao, 1997). However, given that human intake of saponins is generally 200–300 mg/d whereas total food intake is <500 g (dry weight), it is not clear to what extent these results in rodents are relevant to humans (Ridout et al., 1988).

The effect of saponins isolated from soya bean flour on the incidence of aberrant crypt foci (ACF) induced by azoxymethane (AOM) in the colonic wall of CF1 mice was investigated. Four weekly injections of AOM, a known colon carcinogen, were administered to mice. One week after the last injection, mice were placed on an AIN-76 diet supplemented with 3% soya bean saponins or continued on the basal AIN-76 diet. Another group of mice was placed on the saponin diet without AOM initiation to observe the effect of saponins on the growth characteristics of mice. Dietary intake of soya saponins significantly reduced the incidence of ACF at the end of 14 weeks (postinitiation). Noninitiated mice maintained on a similar soya bean saponin-supplemented diet did not show any adverse effects on the growth and overall health of the animals. These findings suggest that soya bean saponins can play an important role in inhibiting the incidence of ACF in the colon of mice (Koratkar and Rao, 1997).

Daidzein, an isoflavone in soybeans, suppresses the growth of HL-60 cells implanted in mouse subrenal capsules (Jing et al., 1993). Genistein inhibits the proliferation of a diversity of both hormone-dependent and hormone-independent cancer cells in vitro with an IC$_{50}$ between 5 and 40 mM (2–10 mg/mL), including breast (Peterson and Barnes, 1991; 1996; Pagliacci et al., 1994; Peterson et al., 1996; So et al., 1996; Clark et al., 1996; Zava and Duwe, 1997), prostate (Peterson and Barnes, 1993; Naik et al., 1994; Kyle et al., 1997), colon (Kuo et
al., 1997; Kuo, 1996), and skin (Rauth et al., 1997) cancer cells (Adlercreutz and Mazur, 1997; Akiyama and Ogawara, 1991; Constantinou and Huberman 1995). Genistein suppresses the metastatic activity of breast (Scholar and Toewa, 1994) and prostate (Santibañez et al., 1997) cancer cells in vitro independent of the effects on cell growth. The anticancer effects of genistein in vitro (Wei et al., 1993) are attributed to its inhibitory effects on enzymes that play a role in signal transduction, including ribosomal S6 kinase (Linassier et al., 1990), MAP kinase (Thorburn and Thorburn, 1994), and tyrosine protein kinases (Akiyama et al., 1987).

Genistein also inhibits the activity of DNA topoisomerase II (Constantinou et al., 1990) and raises the in vitro concentrations of transforming growth factor \( \beta \) (TGF \( \beta \) ) (Peterson et al., 1998) which may suppress growth of cancer cells (Benson and Colletta, 1995; Benson et al., 1996; Markowitz and Roberts, 1997). Genistein has an important role as a potent inhibitor of angiogenesis in vitro (Messina, 1999).

Genistein exerts an inhibitory action on the growth of both estrogen-dependent and estrogen-independent breast cancer cells in vitro, but it is not certain if cellular concentrations of genistein in vivo can reach in vitro concentration capable of suppressing growth of breast cancer cells. Genistein inhibits proliferation of induced serum and epidermal growth factor–stimulated normal human mammary epithelial cells with IC\(_{50}\) values substantially lower than those for transformed human breast epithelial cells (Peterson and Barnes, 1994) suggesting that soy intake may inhibit the initiation of cancer cells, rather than impeding the proliferation of existing cancer cells. Because synergistic effects between genistein and daidzein have been observed in vitro, it would be of interest to examine their concerted action in vivo (Evans et al., 1995; Franke et al., 1995). The possibility remains that other components of soybeans, individually or in conjunction with isoflavones, account for the hypothesized anticancer effects of soyfoods. Wrensch et al (1991), McMichael-Phillips et al (1998), and Cassidy et al (1994; 1995) demonstrated that soy or isoflavones are potentially capable of producing physiological actions related to breast cancer risk. Cassidy et al (1994) noticed that the intake of soy, in particular isoflavone-rich soy (Cassidy et al., 1995), prolongs the follicular phase and circulation levels of gonadotropins. Brown and Lamartiniere (1995), Lamartiniere et al (1995), and Murrill et al (1996) were of the opinion that early consumption of soyfoods by young girls may prevent breast cancer development later in life. Neonatal or prepubertal exposure to genistein inhibits the development of dimethylbenz(a)anthracene-induced mammary tumors in rodents and prolongs the latency period (Brown and Lamartiniere, 1995; Lamartiniere et al., 1995; Murrill et al 1996).

Genistein exerts and antiproliferative action on both androgen-dependent and androgen-independent prostate cancer cells in vitro (Peterson and Barnes, 1993; Naik et al., 1994). It also diminishes the potential of prostate cancer cells to metastasise independent of cell growth inhibition. Concomitantly tyrosine phosphorylation of an unidentified molecular species declines (Santibañez et al., 1997). Though the role played by estrogen in prostate cancer has not been clarified, estrogens are effective in the therapy of metastatic prostate cancer (Pienta and Esper, 1993). Hence the potential estrogenic effects of isoflavones may be protective. Genistein inhibits 5-\( \alpha \)-reductase in genital skin fibroblasts and benign hyperplastic prostate tissue (Evans et al., 1995). This enzyme converts testosterone into a more potent form dihydrotestosterone, which stimulates the growth of prostatic tissue. Ross et al (1992) showed that biomarkers of 5-\( \alpha \)-reductase activity are higher in white and black men compared with Japanese men. The in vitro results of Evans et al (1995) agree with data from Lu et al (1996), showing that following 1 month of soymilk consumption (36 oz/d), the
serum concentration of 3α, 17β-androstanediol glucuronide, a dihydrotestosterone metabolite, was significantly lowered. In mice fed a diet containing soy for 9 months, the incidence of prostatic dysplasia, considered to be a preneoplastic prostate lesion, was significantly diminished. At 12 months, however, difference between the 2 groups was much attenuated. These results are in line with the epidemiologic data noted above and also with the results of a study of MNU-induced prostate tumors in Lobund-Wistar rats (Pollard and Luckert, 1997).

Rats receiving a diet containing soy had a shorter latency period than those fed a diet containing soy high in isoflavones with a small quantity of isoflavones (Pollard and Luckert, 1997). A diet containing soy flour (33% by weight) for 4 months inhibited tumor growth in rats with Dunning R3327 PAP tumors implanted (Zhang et al., 1997). Schleicher et al (1998) Genistein (50 mg/kg body weight) given to rats subcutaneously in the dorsal scapular area every 12 h stranting at the time of tumor cell transplantation inhibited development of prostate tumor implanted with prostate cancer cells and totally inhibited development of lung metastases. Dalu et al (1998) reported that genistein (1 mg genistein/g diet) caused a decline in weight of the dorsolateral and ventral prostates and down-regulated the expression of tyrosine-phosphorylated proteins in rats. genistein dose-dependently inhibited 3H-thymidine incorporation in cultured benign prostatic hynptrophy tissue and prostate cancer tissue (Geller et al., 1998) Although genistein suppressed growth of prostatic cancer cells in vitro, when the metastatic MAT-Lyu prostate cancer cells were injected into the right flank of rats, oral treatment with genistein did not suppress the prostate tumors development (Naik et al., 1994). The doses utilized more closely resembled human dietary intake than those employed in the investigations of Schleicher et al (1998) and Dalu et al (1998). Higher doses of genistein injected intraperitoneally had little effect on tumor growth (Naik et al., 1994). There are limited human data available for use in addressing the soy–prostate cancer hypothesis, although Severson et al (1989) noted that tofu consumption might produce a lower risk of prostate cancer. Isoflavones are detected in the prostatic fluid, at the highest concentrations in men from soyfood-consuming countries (Morton et al., 1997). Isoflavones are concentrated several-fold in the prostatic fluid compared to plasma concentrations.

Genistein inhibits DNA synthesis in human prostate cells in vitro and reduces effect of testosterone in prostate cancer development in rats (Jenkins et al., 2003; Adlercreutz et al., 2000). However, a daily soybean intake sufficient to bring about a decline LDL-cholesterol, does not effect serum concentration of prostate specific antigen (Adlercreutz, 2002). Antifungal proteins (Ma et al., 2009) lectins/hemagglutinins (Lin et al., 2008) and protease inhibitors (Fang et al., 2010) demonstrate antiproliferative activity toward tumor cells in vitro. Some of these show pH stability and thermostability and thus their aforementioned activities may be retained in vivo.

Fotsis et al (1993) observed that genistein at high concentrations interfered with the action of bovine microvascular cells to invade collagen gels and form capillary-like structures when treated with basic fibroblast growth factor. Antiangiogenic agents by preventing tumor-stimulated angiogenesis, inhibit tumor growth beyond a size of 1–2 mm and thus from becoming clinically insignificant (Folkman and Klagsbrun, 1987). A low genistein concentration is required to inhibit angiogenesis in vitro (Adlercreutz and Mazur, 1997).

The antimetastatic activity of soybean saponin has been examined by assessing matrix production of the metalloproteinases MMP-2 and MMP-9 in HT-1080 cells (Kang et al., 2008). MMP-2 and MMP-9 mRNA expression levels were determined by RT-PCR analysis and the levels of secreted MMP-2, MMP-9 and tissue inhibitor of metalloproteinase-2 (TIMP-
Protease Inhibitors, Lectins, Antifungal Protein and Saponins in Soybean

2) were assessed by gelatin zymography and/or ELISA. The invasion of a Matrigel-coated membrane by human fibrosarcoma HT-1080 and HT-29 colon cancer cells was determined by counting the migrated cells. Exposure of HT-1080 cells to soybean saponin diminished the mRNA expression of and attenuated the secretion of MMP-2 and MMP-9. However, the secretion of TIMP-2 was enhanced in a dose-dependent manner. The invasion of HT-1080 cells through a Matrigel-coated membrane was suppressed. The antimetastatic activity of soybean saponin was further confirmed in an in vivo mouse experiment in which CT-26 colon cancer cells were injected via the caudal vein after administering soybean saponin in the diet. The incidence of metastatic tumor colonization of lungs in mice underwent a mild decline 14 days after injection of CT-26 cells via the caudal vein. Thus, soybean saponin reduces tumor cell metastasis by inhibiting production of MMP-2 and MMP-9 production and enhancing TIMP-2 secretion.

The structural resemblance between estrogen, isoflavones and the synthetic isoflavone, 7-isopropoxyisoflavone (ipriflavone), which increases bone mass in postmenopausal women (Valente et al., 1994; Brandi, 1992), inhibits osteoclast activity in vitro (Tsude et al., 1986) raises speculation about the benefits of isoflavones bone health. The ipriflavone has to be metabolized in order to be maximally effective. Daidzein, a soybean isoflavone is one of the metabolites.

That genistein in particular affects bone density in rats (Blair et al., 1996; Fanti et al., 1998). Blair et al (1996) observed that the dry femoral mass of ovariectomized rats fed 30 mmol genistein in particular /day for 4 weeks was 12% higher \( (P < 0.05) \) than that of the controls. In a study by Fanti et al (1998), after 21 days of subcutaneous injection of 5 and 25 mg genistein/g body wt, tibial bone mineral loss in ovariectomized rats was significantly reduced. Potter et al (1998) reported that following 6 months of treatment, lumbar spine bone mineral density was significantly increased in postmenopausal women who had a daily intake of 40 g soy protein containing 2.25 mg isoflavones/g protein, while bone density remained unchanged in women who ingested the same amount of soy protein but containing only 60 % isoflavones (1.39 mg isoflavones/g protein). Some insight has been gained into the possible mechanism(s) regulating the effect of isoflavones on bone health in rats. Isoflavones may both stimulate and inhibit bone formation. Fanti et al (1998) reported that genistein augmented the number of osteoblasts and the serum osteocalcin level, but had no effect on number of osteoclasts.On the other hand, Blair et al (1996) noted that genistein inhibited avian osteoclast protein synthesis in vitro probably due to its inhibitory effects on tyrosine phosphorylation. Estrogen and tamoxifen, which inhibit bone resorption, induce apoptosis in osteoclasts, an effect which is antagonized in vitro by antibodies to TGF-β (Hughes et al., 1996). Since genistein enhanced TGF-β in vitro, the effect of the isoflavone bone resorption may involve TGF-β.

The decrease in hepatic cholesterol synthesis is caused by a decrease in serum insulin concentration because insulin activates an enzyme involved in cholesterol synthesis and, on the other hand, it might be attributed to a change in the hepatic bile acid profile (Mälkki, 2001). The isoflavones in diet containing soybean may retard atherosclerotic progression by virtue of their inhibitory activity toward LDL oxidation, which evokes a series of events forming atherosclerotic plaques. Isoflavones may elicit a cholesterol-lowering action due to interaction with estrogenic receptors, and structural similarity between isoflavones in a diet containing and their metabolites and estrogens. (Anderson et al., 1999). Various clinical studies have disclosed the importance of consumption of soybean protein with its isoflavones to achieve a hypocholesterolemic effect (Lichtenstein, 1998; Farriol et al., 2006).
The Asian diet is rich in soybean foods compared with the western diet (Craig, 1997). Inclusion of isolated soybean protein with isoflavones in the diet of postmenopausal women causes a decline in the incidence of hot flashes (Albertazzi et al., 1998; Setchell and Cassidy, 1999).

In postmenopausal women, isoflavones exert a weak estrogenic action and hence could be exploited as a dietary alternative or supplement to hormone replacement therapy (Setchell and Cassidy, 1999; Duffy et al., 2003). Improved cognitive ability was observed in postmenopausal women after intake of soybean extract containing isoflavones. Two types of estrogenic receptors (ER-α and ER-β) are found in the brain. Isoflavones bind preferentially to ER-β receptors, which play a role in cognitive function and are found in abundance in brain regions involved in cognition (Duffy et al., 2003).

From the foregoing account it can be seen that isoflavones represent important bioactive components of soybean. In addition, protease inhibitors, lectins and antifungal proteins in soybean display a multiplicity of health promoting activities such as antitumor, mitogenic and antimicrobial activities (Table 1). Hence the intake of soybean is beneficial to health.

6. Conclusion

The above review of literature has revealed that protease inhibitors in some cultivars of soybean have marked thermostability and pH stability and may account for the reduced incidence of cancer in populations favouring a diet rich in soybeans. Soybean saponins also may account for part of the antitumor activity in soybeans. Soybean saponins also display other health promoting effects such as anti-osteoporotic activity. Lectins and antifungal proteins also exhibit antitumor and other activities. Thus a regular dietary intake of soybeans is beneficial to health and should be encouraged.

<table>
<thead>
<tr>
<th>Bioactive components of soybean</th>
<th>Biological activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protease inhibitors</td>
<td>Antitumor, HIV-1 reverse transcriptase inhibitory (Bowman – Birk and Kunitz types)</td>
</tr>
<tr>
<td>Lectin</td>
<td>Antitumor, HIV-1 reverse transcriptase inhibitory</td>
</tr>
<tr>
<td>Antifungal protein</td>
<td>Antifungal, HIV-1 reverse transcriptase inhibitory, anti-mitogenic</td>
</tr>
<tr>
<td>Saponins</td>
<td>Hypocholesterolemic, anti-atherosclerotic, increase bone mineral density</td>
</tr>
</tbody>
</table>

Table 1. Bioactive components of soybean and their biological activities
7. References


www.intechopen.com


Soybean is an agricultural crop of tremendous economic importance. Soybean and food items derived from it form dietary components of numerous people, especially those living in the Orient. The health benefits of soybean have attracted the attention of nutritionists as well as common people.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: